Durability of Humoral Immune Responses to SARS-CoV-2 in Citizens of Ariano Irpino (Campania, Italy): A Longitudinal Observational Study With an 11.5-Month Follow-Up.
SARS-CoV-2
antibody response
immunoassay
screening
seroprevalence
Journal
Frontiers in public health
ISSN: 2296-2565
Titre abrégé: Front Public Health
Pays: Switzerland
ID NLM: 101616579
Informations de publication
Date de publication:
2021
2021
Historique:
received:
25
10
2021
accepted:
25
11
2021
entrez:
3
1
2022
pubmed:
4
1
2022
medline:
8
1
2022
Statut:
epublish
Résumé
As of November 17, 2021, SARS-CoV-2 (Severe Acute Respiratory Syndrome CoronaVirus 2), the causative agent of COVID-19 (COronaVIrus Disease 19), has infected ~250 million people worldwide, causing around five million deaths. Titers of anti-SARS-CoV-2 neutralizing antibodies were relatively stable for at least 9 months in a population-based study conducted in Wuhan, China, both in symptomatic and in asymptomatic individuals. In the mass screening campaign conducted in the town of Ariano Irpino (Avellino, Italy) in May, 2020, 5.7% (95% CI: 5.3-6-1) of the 13,444 asymptomatic citizens screened were positive for anti-nucleocapsid antibodies against SARS-CoV-2. Among these, 422 citizens were re-tested for anti SARS-CoV-2 antibodies in January, 2021 and/or in April, 2021 and enrolled in this longitudinal observational study. Median (interquartile range) age of the study cohort was 46 years (29-59), with 47 (11.1%) participants of minor age, while 217 (51.4%) participants were females. There was no evidence of re-infection in any of the subjects included. Presence of anti-nuclear antibodies antibodies (Elecysis, Roche) was reported in 95.7 and 93.7% of evaluable participants in January and April, 2021. Multiple logistic regression analysis used to explore associations between age, sex and seroprevalence showed that adults vs. minors had significantly lower odds of having anti-S1 antibodies (Biorad) both in January, 2021 and in April, 2021. Our findings showed that antibodies remained detectable at least 11.5 months after infection in >90% of never symptomatic cases. Further investigation is required to establish duration of immunity against SARS-CoV-2.
Identifiants
pubmed: 34976939
doi: 10.3389/fpubh.2021.801609
pmc: PMC8718636
doi:
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
801609Informations de copyright
Copyright © 2021 Coppola, Buonerba, Cardinale, Lo Conte, Sansone, Rofrano, De Vita, Morgante, Triassi, Atripaldi, Brambilla, Sabatino, Pierri, Pacella, Pizzolante, Pierri, Ferrucci, Zollo, Capasso, Stringhini, Ascierto, Roperto and Cerino.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Nature. 2020 Aug;584(7821):437-442
pubmed: 32555388
Lancet Infect Dis. 2021 Jan;21(1):52-58
pubmed: 33058797
FEBS Lett. 2006 Oct 16;580(24):5612-20
pubmed: 16989815
Lancet Infect Dis. 2020 Dec;20(12):1390-1400
pubmed: 32979318
Emerg Microbes Infect. 2021 Dec;10(1):774-781
pubmed: 33830901
Lancet. 2021 Mar 20;397(10279):1075-1084
pubmed: 33743869
Future Sci OA. 2021 Jan 12;7(4):FSO673
pubmed: 33815819
Science. 2021 Feb 5;371(6529):
pubmed: 33408181
Int J Infect Dis. 2020 Dec;101:314-322
pubmed: 33045429
J Infect Dis. 2021 Feb 3;223(2):197-205
pubmed: 33535236
Microbiol Spectr. 2021 Sep 3;9(1):e0034121
pubmed: 34346750
J Virol. 2006 Jan;80(2):941-50
pubmed: 16378996
Clin Chem Lab Med. 2020 Oct 25;58(11):e251-e253
pubmed: 32692698
Med (N Y). 2021 Mar 12;2(3):313-320.e4
pubmed: 33554155
Lancet. 2020 Nov 14;396(10262):1595-1606
pubmed: 33065034
Int J Surg. 2014 Dec;12(12):1495-9
pubmed: 25046131
BMC Infect Dis. 2021 Aug 30;21(1):889
pubmed: 34461847
Clin Infect Dis. 2021 Nov 2;73(9):e2946-e2951
pubmed: 32840608
Clin Biochem. 2021 Nov;97:54-61
pubmed: 34453893